Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?

被引:55
作者
Jungner, I
Sniderman, AD [1 ]
Furberg, C
Aastveit, AH
Holme, I
Walldius, G
机构
[1] Royal Victoria Hosp, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada
[2] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden
[3] CALAB Res, Stockholm, Sweden
[4] Karolinska Hosp, King Gustaf V Res Inst, S-10401 Stockholm, Sweden
[5] Astra Zeneca, Molndal, Sweden
[6] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA
[7] Agr Univ Norway, Dept Math Sci, N-1432 As, Norway
[8] Ulleval Hosp, Ctr Prevent Med, Oslo, Norway
关键词
D O I
10.1016/j.amjcard.2005.10.062
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The lipoprotein-related risk of coronary artery disease is determined principally by the balance between atherogenic lipoprotein particles, i.e., the lipoprotein that contain apolipoprotein-B (apo-B), and the antiatherogenic particles, i.e., high-density lipoprotein particles that contain apo-A-I. However, there is also considerable evidence that patients with predominantly small dense low-density lipoprotein (LDL) have more adverse clinical outcomes than do those with large buoyant LDL. The AMORIS study prospectively examined the relative importance of lipoprotein lipids versus apolipoproteins on the risk of fatal myocardial infarction in a large Swedish cohort. This updated analysis includes 69,029 men and 57,167 women who were followed for a mean of 10.3 years. Our objective was to determine whether LDL size as reflected by the LDL cholesterol/apo-B ratio added significant predictive power to apo-B or the apo-B/apo-A-I ratio. Although apo-A-I added significantly to the predictive power of apo-B, categorical and continuous multivariate analyses showed that this is not the case for LDL size. The strongest single lipoprotein-related risk factor was the apo-B/apo-A-I ratio. In conclusion, these results provide further confirmation of the importance of determining apo-B and apo-A-I in routine clinical practice. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:943 / 946
页数:4
相关论文
共 21 条
[1]   LDL PARTICLE-SIZE DISTRIBUTION - RESULTS FROM THE FRAMINGHAM OFFSPRING STUDY [J].
CAMPOS, H ;
BLIJLEVENS, E ;
MCNAMARA, JR ;
ORDOVAS, JM ;
POSNER, BM ;
WILSON, PWF ;
CASTELLI, WP ;
SCHAEFER, EJ .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (12) :1410-1419
[2]  
CORESH J, 1993, J LIPID RES, V34, P1687
[3]   Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The Framingham study [J].
Freedman, DS ;
Otvos, JD ;
Jeyarajah, EJ ;
Shalaurova, I ;
Cupples, LA ;
Parise, H ;
D'Agostino, RB ;
Wilson, PWF ;
Schaefer, EJ .
CLINICAL CHEMISTRY, 2004, 50 (07) :1189-1200
[4]   APOLIPOPROTEIN-B AND APOLIPOPROTEIN-A-I IN RELATION TO SERUM-CHOLESTEROL AND TRIGLYCERIDES IN 43,000 SWEDISH MALES AND FEMALES [J].
JUNGNER, I ;
WALLDIUS, G ;
HOLME, I ;
KOLAR, W ;
STEINER, E .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1992, 21 (03) :247-255
[5]  
Jungner I, 1998, CLIN CHEM, V44, P1641
[6]   Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study [J].
Lamarche, B ;
Moorjani, S ;
Lupien, PJ ;
Cantin, B ;
Bernard, PM ;
Dagenais, GR ;
Despres, JP .
CIRCULATION, 1996, 94 (03) :273-278
[7]   PREVALENCE OF DYSLIPIDEMIC PHENOTYPES IN ISCHEMIC-HEART-DISEASE (PROSPECTIVE RESULTS FROM THE QUEBEC CARDIOVASCULAR STUDY) [J].
LAMARCHE, B ;
DESPRES, JP ;
MOORJANI, S ;
CANTIN, B ;
DAGENAIS, GR ;
LUPIEN, PJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (17) :1189-1195
[8]  
MARCOVINA SM, 1993, CLIN CHEM, V39, P773
[9]  
MARCOVINA SM, 1994, CLIN CHEM, V40, P586
[10]  
PACKARD CJ, 2002, ARTERIOSCLER THROMB, V22, P274